Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allena Pharmaceuticals, Inc.ALNA · Entity 130904 | Chief Financial Officer | December 17, 2020 | December 18, 2020 |
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Director | October 01, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allena Pharmaceuticals, Inc.
Report date December 17, 2020 · Filed December 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 121,272 |
Reported balance
After 2020-12-17 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-12-17 · Sale · Disposed 68,550 · Balance 121,272 F1: The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units |
| Common StockSEC Table I · non-derivative | Direct | 189,822 |
Reported balance
After 2020-12-17 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-12-17 · Exercise / conversion · Acquired 164,822 · Balance 189,822 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-17 · Exercise / conversion · Disposed 164,822 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: On December 2, 2019, the Reporting Person was granted 82,411 restricted stock units, vesting in two equal installments on June 2, 2020 and December 2, 2020 (the "December 2019 Grant"). On May 28, 2020, the reporting person was granted an additional 82,411 restricted stock units (the "May 2020 Grant") and the December 2019 Grant was amended to vest in full, together with the May 2020 Grant, on December 2, 2020. 164,822 shares of common stock were distributed to the Reporting Person on December 17, 2020 following the vesting of the restricted stock units from the December 2019 Grant and the May 2020 Grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: On December 2, 2019, the Reporting Person was granted 82,411 restricted stock units, vesting in two equal installments on June 2, 2020 and December 2, 2020 (the "December 2019 Grant"). On May 28, 2020, the reporting person was granted an additional 82,411 restricted stock units (the "May 2020 Grant") and the December 2019 Grant was amended to vest in full, together with the May 2020 Grant, on December 2, 2020. 164,822 shares of common stock were distributed to the Reporting Person on December 17, 2020 following the vesting of the restricted stock units from the December 2019 Grant and the May 2020 Grant.
KORU Medical Systems, Inc.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,431 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 5,119 · Balance 56,431 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 1, 2026 21:23 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,119 | $2.93 | $14,998.67 |
DisclosureSEC source: 0001161697-26-000225 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,431 Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 21:21 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,571 | $4.20 | $14,998.20 |
DisclosureSEC source: 0001161697-26-000151 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,312 Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 20:48 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,472 | $4.32 | $14,999.04 |
DisclosureSEC source: 0001161697-26-000084 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,741 Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:51 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 2,581 | $5.81 | $14,995.61 |
DisclosureSEC source: 0001161697-26-000013 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,269 Read SEC document |
| October 02, 2025 Filed Oct 2, 2025 20:41 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,916 | $3.83 | $14,998.28 |
DisclosureSEC source: 0001161697-25-000340 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,688 Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:56 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 4,189 | $3.58 | $14,996.62 |
DisclosureSEC source: 0001161697-25-000205 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,772 Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:30 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,870 | $2.56 | $15,027.20 |
DisclosureSEC source: 0001161697-25-000135 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,583 Read SEC document |
| January 03, 2025 Filed Jan 3, 2025 21:29 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,937 | $3.81 | $14,999.97 |
DisclosureSEC source: 0001161697-25-000022 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,713 Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:06 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,454 | $2.75 | $14,998.50 |
DisclosureSEC source: 0001161697-24-000411 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,776 Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 14:42 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,545 | $2.71 | $15,026.95 |
DisclosureSEC source: 0001161697-24-000310 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,322 Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 20:13 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 6,329 | $2.37 | $14,999.73 |
DisclosureSEC source: 0001161697-24-000174 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,777 Read SEC document |
| December 31, 2023 Filed Jan 2, 2024 21:54 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 6,329 | $2.37 | $14,999.73 |
DisclosureSEC source: 0001161697-24-000013 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,448 Read SEC document |
| September 30, 2023 Filed Oct 6, 2023 20:05 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 119 | $2.74 | $326.06 |
DisclosureSEC source: 0001161697-23-000526 · form_4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119 Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:15 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | Exercise / conversionRestricted Stock Units · Derivative | 164,822 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034479 · doc4.xml · derivative · entry 3 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,822 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On December 2, 2019, the Reporting Person was granted 82,411 restricted stock units, vesting in two equal installments on June 2, 2020 and December 2, 2020 (the "December 2019 Grant"). On May 28, 2020, the reporting person was granted an additional 82,411 restricted stock units (the "May 2020 Grant") and the December 2019 Grant was amended to vest in full, together with the May 2020 Grant, on December 2, 2020. 164,822 shares of common stock were distributed to the Reporting Person on December 17, 2020 following the vesting of the restricted stock units from the December 2019 Grant and the May 2020 Grant. F3 · derivative.expiration_date: On December 2, 2019, the Reporting Person was granted 82,411 restricted stock units, vesting in two equal installments on June 2, 2020 and December 2, 2020 (the "December 2019 Grant"). On May 28, 2020, the reporting person was granted an additional 82,411 restricted stock units (the "May 2020 Grant") and the December 2019 Grant was amended to vest in full, together with the May 2020 Grant, on December 2, 2020. 164,822 shares of common stock were distributed to the Reporting Person on December 17, 2020 following the vesting of the restricted stock units from the December 2019 Grant and the May 2020 Grant. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:15 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | Exercise / conversionCommon Stock | 164,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-034479 · doc4.xml · nonDerivative · entry 2 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:15 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | SaleCommon Stock | 68,550 | $1.36 | $93,228.00 |
DisclosureSEC source: 0000899243-20-034479 · doc4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,272 F1 · kind: The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units Read SEC document |
| May 28, 2020 Filed May 29, 2020 17:56 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantRestricted Stock Units · Derivative | 82,411 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014585 · doc4.xml · derivative · entry 2 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,411 Underlying: Common Stock · 82,411 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: 100% shall vest on December 2, 2020. F3 · derivative.expiration_date: 100% shall vest on December 2, 2020. Read SEC document |
| May 28, 2020 Filed May 29, 2020 17:56 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantRestricted Stock Units · Derivative | 82,411 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014585 · doc4.xml · derivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,411 Underlying: Common Stock · 82,411 shares Expires not disclosed F1 · security: This restricted stock unit award was previously reported on a Form 4 filed on 12/4/2019. In connection with the new award also reported on this Form 4, this award was amended on May 28, 2020 such that it will now vest in full on December 2, 2020 rather than in two installments. The new award and the amended award are intended to provide additional retentive value to the recipient. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: 100% shall vest on December 2, 2020. F3 · derivative.expiration_date: 100% shall vest on December 2, 2020. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:28 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantStock Option (Right to Buy) · Derivative | 153,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0000899243-19-028520 · doc4.xml · derivative · entry 2 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 153,000 shares Expires 2029-12-01 F3 · derivative.exercise_date: Shares vest in 48 equal monthly installments beginning January 2, 2020. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:28 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantRestricted Stock Units · Derivative | 82,411 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028520 · doc4.xml · derivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,411 Underlying: Common Stock · 82,411 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: 50% shall vest on June 2, 2020 and the remaining 50% shall vest on December 2, 2020. F2 · derivative.expiration_date: 50% shall vest on June 2, 2020 and the remaining 50% shall vest on December 2, 2020. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 19:56 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0000899243-19-005943 · doc4.xml · derivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-03-04 F1 · derivative.exercise_date: Stock option shall vest and become exercisable in 48 equal monthly installments beginning on the one month anniversary of February 19, 2019. Read SEC document |
| May 09, 2018 Filed May 10, 2018 11:27 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-18-029082 · doc4.xml · derivative · entry 2 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,031 Underlying: Common Stock · 25,000 shares Expires 2026-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on June 20, 2017 and the remaining shares vest in 36 equal monthly installments thereafter Read SEC document |
| May 09, 2018 Filed May 10, 2018 11:27 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | Exercise / conversionCommon Stock | 25,000 | $1.59 | $39,750.00 |
DisclosureSEC source: 0001209191-18-029082 · doc4.xml · nonDerivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 16:13 UTC | Allena Pharmaceuticals, Inc. ALNA · Entity 130904 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001209191-18-009174 · doc4.xml · derivative · entry 1 WHOLIHAN EDWARD · CIK 0001719764 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: Shares vest in 48 equal monthly installments beginning March 9, 2018 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.